All articles by Annabel Kartal Allen

Annabel Kartal Allen

Annabel Kartal-Allen is a reporter for Clinical Trials Arena, Pharmaceutical Technology and Medical Device Network based in London, UK. Annabel holds interests in oncology, neurology and metabolic diseases. She has previous experience reporting for both the pharmaceutical and nutraceutical industries, and holds a BSc in Biology from the University of Sussex. Contact Annabel

Rivermark pockets $20m in Series D for late-stage prostate device trial

Wisconsin-based medtech Rivermark Medical has secured $20m in a Series D financing round – supporting the company’s late-stage clinical activities…
Bayesian Health secures first FDA clearance for AI-driven continuous sepsis monitor

The US Food and Drug Administration (FDA) has cleared Bayesian Health’s continuous artificial intelligence (AI)-driven sepsis monitor, making the device…
WhiteSwell’s heart failure device promising but patient death rattles results

WhiteSwell has debuted promising early data from a feasibility study on its eLym system in acute decompensated heart failure (ADHF),…
DDW 2026: key readouts from the conference

At the 2026 Digestive Disease Week (DDW) conference, there was significant buzz around certain pharma and medical device readouts, with…
J&J’s soft tissue surgical robot succeeds in pivotal gastric bypass study

Johnson & Johnson (J&J) is eyeing a De Novo classification from US regulators for its Ottava Robotic Surgical System, after…

Merck KGaA and Remepy join forces to develop combo drug-digital therapies

Merck KGaA has inked a collaboration deal with Israeli-US startup, Remepy, to explore the therapeutic potential of combination drug and…
HRS 2026: Medtronic, Boston Scientific and Abbott debut key PFA data

Boston Scientific, Abbott and Medtronic all presented successful readouts of their cardiac devices during the Heart Rhythm Society’s (HRS) 2026…
Roche builds MRD testing arsenal in $595m Saga Diagnostics buyout

Roche has agreed to acquire molecular residual disease (MRD) specialist, Saga Diagnostics and its platform in a $595m bid –…
Biomarker-led trials to guide the future of precision psychiatry

As the neuroscience treatment landscape continuously evolves towards the wider use of precision treatment options, biomarker-led trials are emerging as…
Boehringer hands over $50m and market rights for Click’s digital therapeutic

Boehringer Ingelheim and Click Therapeutics have shifted the dynamic of their long-term collaboration, which will see Click take the commercialisation…